Chronic treatment with the fatty acid amide hydrolase (FAAH) inhibitor URB597 ameliorates CCH-induced NVU impairment by reducing SENP3 levels (Wang et al., 2017). Here, FAAH is linked to columnar cell hyperplasia of the breast.